Aditxt, Inc. (ADTX) Stock

Aditxt, Inc. is a pioneering biotechnology company focused on advancing technologies that enhance immune system health through immune mapping and reprogramming. Central to its innovation is AditxtScore, a platform enabling individuals to comprehensively understand, manage, and monitor their immune profiles, providing crucial insights into potential immune system attacks and responses. Additionally, the company is developing Apoptotic DNA Immunotherapy, a nucleic acid-based technology designed to induce tolerance to the body's own tissues, mirroring natural mechanisms.

Beyond immune profiling, Aditxt, Inc. is expanding its portfolio with ADi products tailored for various applications including organ transplantation, skin grafting, autoimmune diseases, and allergies. These initiatives underscore the company's commitment to pioneering therapeutic solutions that address critical medical needs through cutting-edge biotechnological approaches. Aditxt, Inc. collaborates through license agreements with esteemed institutions such as Loma Linda University and Leland Stanford Junior University, further enhancing its research and development capabilities.

Founded in 2017 and headquartered in Richmond, Virginia, Aditxt, Inc. (formerly known as ADiTx Therapeutics, Inc.) continues to drive innovation in biotechnology with a focus on transforming immune health management. With its strategic partnerships and robust pipeline, the company is poised to make significant advancements in immune system therapeutics and diagnostics, offering promising solutions for improving patient outcomes globally.